Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)

  • Diffuse Large B-Cell Lymphoma
Trial Status:


This trial runs in
  • Marlow
Trial Identifier:

NCT02708732 ML29956

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This study is a prospective, cross-sectional survey to be administered to real patients in remission from DLBCL using a 15-minute postal or online survey. The project is designed to describe the impact of DLBCL remission on health utility and quality of life. Data collection will occur over a 4-month period.

      Hoffmann-La Roche Sponsor
      NCT02708732 , ML29956 Trial Identifier
      Diffuse Large B-Cell Lymphoma Condition
      Official Title

      UK Utility Study in Diffuse Large B-Cell Lymphoma

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Adults greater than or equal to (>/=) 18 years of age
      • Diagnosis of DLBCL and currently in first remission
      • Prior drug treatment for DLBCL
      Exclusion Criteria
      • Receiving active treatment for DLBCL
      • Relapsed following any treatment for DLBCL

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now